AKT1 and cancer: The oncogenic activation of the PI3K/AKT/mTORC1 pathway can also inhibit ferroptosis in cancer cells through downstream SREBP1/scd1-mediated adipogenesis, so the combination of mTOR inhibitors and other ferroptosis inducers for cancer treatment may be an excellent therapeutic target [86].